title: Advancing the development of tuberculosis therapy.
abstract: Although the development of novel drugs and combination regimens for tuberculosis has accelerated in recent years, the pipeline remains thin and major challenges remain to be addressed in efficiently evaluating newer drugs to improve treatment outcomes, shorten duration of therapy and tackle drug resistance.
authors.affiliation: Division of Infection and Immunity, University College London, London NW3 2PF, UK. a.zumla@ucl.ac.uk
authors.forename: Alimuddin
authors.initials: A
authors.lastname: Zumla
authors.forename: Richard
authors.initials: R
authors.lastname: Hafner
authors.forename: Christian
authors.initials: C
authors.lastname: Lienhardt
authors.forename: Michael
authors.initials: M
authors.lastname: Hoelscher
authors.forename: Andrew
authors.initials: A
authors.lastname: Nunn
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D064687:Diarylquinolines; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000254:growth & development; D011804:Quinolines / Q000737:chemistry / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000995:Antitubercular Agents; D064687:Diarylquinolines; D011804:Quinolines; C493870:bedaquiline